Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia
Status:
Terminated
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether improvement in P50 (a pharmacodynamic
marker) in auditory sensory gating is demonstrated after administration of TAK-058 and
ondansetron compared to placebo in participants with schizophrenia.